智通财经APP讯,石四药集团(02005)公布,该集团的盐酸屈他维林已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸屈他维林是一种解痉药,主要用于治疗胆道、泌尿道和胃肠道痉挛。
智通财经APP讯,石四药集团(02005)公布,该集团的盐酸屈他维林已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸屈他维林是一种解痉药,主要用于治疗胆道、泌尿道和胃肠道痉挛。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.